Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01733589

Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

Stage III Non-small-Cell Lung Cancer Clinical Trial

Official title:
Multicenter Phase I/II Clinical Trial of Recombinant Human Endostatin Continued Pumping Into Vein Combining With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer

Clinical Trial Summary

Resistance of hypoxic tumor cells to radiation is a significant reason of failure in the local control of tumors, especially the squamous cell carcinomas. Preclinical models have shown that Endostar may transiently "normalize" the tumor vasculature to make it more efficient for oxygen delivery, thereby providing a window of opportunity for enhanced sensitivity to radiation treatment. This study is to evaluate the safety, toxicity, and efficacy of the addition of Endostar Continued Pumping into Vein to the standard CCRT regimen in patients with unresectable stage III NSCLC.

Clinical Trial Description

Primary

Evaluate the efficacy and safety of Endostar combined with concurrent chemo-radiotherapy (CCRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).

Secondary

Measure changes in VEGF and other angiogenic cytokines and antiangiogenic factors in plasma samples from these patients.

Evaluate the application of CT perfusion imaging to determine changes in tumor vascular mophology and function during treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01733589
Study type Interventional
Source Zhejiang Cancer Hospital
Contact
Status Completed
Phase Phase 1/Phase 2
Start date November 2012
Completion date June 2015
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04085250 - Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy Phase 2
Recruiting NCT03742687 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC N/A
Recruiting NCT04325763 - A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) Phase 3
Active, not recruiting NCT03589547 - Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung Phase 2
Not yet recruiting NCT04304638 - Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
Active, not recruiting NCT01576796 - Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer Phase 2
Recruiting NCT04441138 - Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC Phase 2
Not yet recruiting NCT04181372 - A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer Phase 2
Terminated NCT03871153 - Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer Phase 2
Completed NCT05331833 - Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.